These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25769547)

  • 1. High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.
    Karimi M; Nilsson C; Dimitriou M; Jansson M; Matsson H; Unneberg P; Lehmann S; Kere J; Hellström-Lindberg E
    Haematologica; 2015 Jun; 100(6):e223-5. PubMed ID: 25769547
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.
    McGraw KL; Nguyen J; Komrokji RS; Sallman D; Al Ali NH; Padron E; Lancet JE; Moscinski LC; List AF; Zhang L
    Haematologica; 2016 Aug; 101(8):e320-3. PubMed ID: 27081179
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and
    Martin-Cabrera P; Jeromin S; Perglerovà K; Haferlach C; Kern W; Haferlach T
    Haematologica; 2017 Apr; 102(4):e125-e128. PubMed ID: 28057736
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Nardi V; Hasserjian RP
    Surg Pathol Clin; 2016 Mar; 9(1):143-63. PubMed ID: 26940274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SETBP1 mutation analysis in 944 patients with MDS and AML.
    Thol F; Suchanek KJ; Koenecke C; Stadler M; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Kade S; Löffeld P; Banihosseini S; Bug G; Ottmann O; Hofmann WK; Krauter J; Kröger N; Ganser A; Heuser M
    Leukemia; 2013 Oct; 27(10):2072-5. PubMed ID: 23648668
    [No Abstract]   [Full Text] [Related]  

  • 8. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.
    Gillis NK; Ball M; Zhang Q; Ma Z; Zhao Y; Yoder SJ; Balasis ME; Mesa TE; Sallman DA; Lancet JE; Komrokji RS; List AF; McLeod HL; Alsina M; Baz R; Shain KH; Rollison DE; Padron E
    Lancet Oncol; 2017 Jan; 18(1):112-121. PubMed ID: 27927582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia.
    Gong Z; Xu ML; Chen M; Cui W; Kantarjian HM; Cortes JE; Zhou T; Tang G; Wang W; Medeiros LJ; Hu S
    Am J Hematol; 2019 Oct; 94(10):E256-E259. PubMed ID: 31273842
    [No Abstract]   [Full Text] [Related]  

  • 10. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
    El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
    Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
    Kohlmann A; Bacher U; Schnittger S; Haferlach T
    Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of NUP98/NSD1 translocations in adult AML and MDS patients.
    Thol F; Kölking B; Hollink IH; Damm F; van den Heuvel-Eibrink MM; Michel Zwaan C; Bug G; Ottmann O; Wagner K; Morgan M; Hofmann WK; Göhring G; Schlegelberger B; Krauter J; Ganser A; Heuser M
    Leukemia; 2013 Mar; 27(3):750-4. PubMed ID: 22929522
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
    Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
    Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathologic features of secondary acute promyelocytic leukemia.
    Duffield AS; Aoki J; Levis M; Cowan K; Gocke CD; Burns KH; Borowitz MJ; Vuica-Ross M
    Am J Clin Pathol; 2012 Mar; 137(3):395-402. PubMed ID: 22338051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Forghieri F; Paolini A; Morselli M; Bigliardi S; Bonacorsi G; Leonardi G; Coluccio V; Maccaferri M; Fantuzzi V; Faglioni L; Colaci E; Soci F; Nasillo V; Messerotti A; Arletti L; Pioli V; Zucchini P; Quadrelli C; Corradini G; Giacobbi F; Vallerini D; Riva G; Barozzi P; Lagreca I; Marasca R; Narni F; Mecucci C; Ottaviani E; Martinelli G; Falini B; Luppi M; Potenza L
    Leuk Lymphoma; 2015; 56(11):3222-6. PubMed ID: 25813079
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.
    Shih AH; Chung SS; Dolezal EK; Zhang SJ; Abdel-Wahab OI; Park CY; Nimer SD; Levine RL; Klimek VM
    Haematologica; 2013 Jun; 98(6):908-12. PubMed ID: 23349305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia.
    Thol F; Scherr M; Kirchner A; Shahswar R; Battmer K; Kade S; Chaturvedi A; Koenecke C; Stadler M; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Bug G; Ottmann O; Hofmann WK; Kröger N; Fiedler W; Schlenk R; Döhner K; Döhner H; Krauter J; Eder M; Ganser A; Heuser M
    Haematologica; 2015 Apr; 100(4):e122-4. PubMed ID: 25552704
    [No Abstract]   [Full Text] [Related]  

  • 19. RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome.
    Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
    Leuk Lymphoma; 2019 May; 60(5):1334-1336. PubMed ID: 30997874
    [No Abstract]   [Full Text] [Related]  

  • 20. Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
    Bigenwald C; Harel S; Chevignon F; Roos-Weil D; Bernard OA; Amorim S; Brice P; Adès L; Nloga AM; Sébert M; Braun T; Eclache V; Thieblemont C; Fenaux P
    Br J Haematol; 2018 Jan; 180(2):304-308. PubMed ID: 27662562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.